Recombinant live attenuated measles virus-based vaccines inducing comprehensive protection against Ebola and Marburg viruses.

Filoviruses, including Ebola and Marburg viruses, present significant global health challenges due to their high mortality rates. Despite the availability of several Ebola virus vaccines, none provide cross-protection against multiple filovirus species. In this study, we developed recombinant live attenuated measles virus-based vaccine candidates designed to express Ebola or Marburg virus glycoproteins and generate virus-like particles for pan-filovirus immunization. The administration of these candidates by intraperitoneal injection into IFNAR-/- mice elicited robust antibody and cellular immune responses specific to Ebola and Marburg virus glycoproteins, with virus-like particles expressing candidates inducing the strongest immunity. Importantly, all vaccines containing Ebola virus glycoproteins afforded complete protection against mouse-adapted Ebola virus; meanwhile, those with Marburg glycoproteins provided protection against lethal replication competent vesicular stomatitis virus-Marburg virus challenges. These findings support the potential of measles virus-based vectors and virus-like particles as promising platforms for the development of vaccines targeting multiple filoviruses.